Freenome, Inc. (FRNM) Fair Value 2026

FRNM · Diagnostics & Research ·

By CirclFi Research Team · Data from SEC EDGAR, FRED & GDELT

Quality Score

4.8 /10

32 fundamental signals · 1 models active

Value Trap Risk

LOW (32/100)

Quick Summary — As of 2026-08-27, Freenome, Inc. (FRNM) trades at $13.94. QOC: 4.8/10. Value Trap Risk: 32/100 (LOW). 1/13 models active.

Key Facts

Ticker
FRNM
Price
$13.94
Quality Score
4.8/10
Value Trap Risk
32/100
Models Active
1/13
Last Updated
Strength: 1 independent models provide multi-angle coverage
Risk: Below-average Quality Score of 4.8/10 signals weak fundamentals

What Fair Value Does Each Model Give FRNM?

1 Intrinsic Value Models vs. Current Price ($13.94)

Core Models (Unlocked)
Model Fair Value Upside
Relative · Low Conviction
 $0.22 -98.4%

All Models Active

All 1 models are displayed above.

What Is Freenome, Inc. (FRNM) Worth in 2026?

According to the CirclFi Deep Alpha Valuation Engine, Freenome, Inc.'s intrinsic value is estimated at $0.22, suggesting the stock is overvalued at its current price of $13.94. With 1 out of 1 models flagging downside (-98.4% vs price), the market may be pricing in unsustainable growth.

What Do the Models Say About FRNM?

1 of 13 models are currently active for FRNM. All 1 active models suggest the stock trades above fair value. See which stocks rank higher →

How Does FRNM Rank in Diagnostics & Research?

Among 52 Diagnostics & Research stocks, FRNM ranks #44 by Quality of Company score. CirclFi's QOC score of 4.8/10 evaluates 32 fundamental signals. A score of 4.8 reflects mixed fundamentals.

As a healthcare company, Freenome, Inc. operates in a sector where revenue per drug is a critical driver of valuation. Investors evaluating FRNM should weigh these sector-specific dynamics alongside our model-derived fair values.

Is FRNM a Value Trap?

CirclFi's Value Trap algorithm assigns FRNM a score of 32/100 (LOW). This indicates low risk. The financial profile does not exhibit typical value trap warning signs. The score cross-references apparent undervaluation against fundamental deterioration signals. Browse lowest value-trap stocks →

Multi-Model Methodology

1 of 13 models are active for Freenome, Inc.. Limited activation may indicate insufficient history. Each model applies a fundamentally different valuation philosophy. See the complete methodology →

According to the CirclFi 32-factor quality framework, Freenome, Inc.'s fundamental quality profile registers 4.8/10. This mixed score captures the company's profitability depth, growth consistency, balance sheet resilience, and shareholder return track record.

CirclFi runs 13 independent models for each stock. Browse all stocks with 13-model coverage →

Data Sources & Confidence

Every FRNM valuation is built from SEC EDGAR XBRL filings — 700+ standardized financial tags. Macroeconomic context from FRED calibrates discount rates, while GDELT news sentiment feeds into our Sentiment SOTP model. All pipelines run daily. Read the complete data methodology →

Across FRNM's 1 active models, average confidence is 5%. Lower confidence may reflect limited history or high volatility.

CirclFi's output is a research starting point, not a buy/sell signal. All data updates daily. Read the full methodology →

This analysis is produced by the CirclFi Valuation Engine using quantitative models applied to SEC EDGAR filings, public market feeds, and FRED macroeconomic indicators. It is not financial advice.

Read the full investment analysis: Should You Buy Freenome, Inc. Stock in 2026? →

Bull case, bear case, risk factors & peer comparison — updated daily

Which Similar Diagnostics & Research Stocks Should You Also Analyze?

11 related Diagnostics & Research stocks with 13-model coverage

ISPCiSpecimen Inc.QOC 4.8PRPHProPhase Labs, Inc.QOC 4.8BIAFbioAffinity Technologies, Inc.QOC 5.0NSTMNovelStem International Corp.QOC 4.2ADVBAdvanced Biomed Inc.QOC 5.0NDRAENDRA Life Sciences Inc.QOC 4.0ILMNIllumina, Inc.QOC 8.8RVTYRevvity, Inc.QOC 7.4BNRBurning Rock Biotech LimitedQOC 6.5IDXXIDEXX Laboratories, Inc.QOC 9.5MEDPMedpace Holdings, Inc.QOC 9.3

Read investment analysis: ISPC · PRPH · BIAF · NSTM · ADVB · NDRA · ILMN · RVTY · BNR · IDXX · MEDP

Which Other Stocks Have a Similar Quality Score to FRNM?

7 companies across all industries closest to FRNM’s Quality of Company score of 4.8/10.

THMGThunder Mountain Gold, Inc.QOC 4.8UONEUrban One, Inc.QOC 4.8HSLVHighlander Silver Corp.QOC 4.8FWDIForward Industries, Inc.QOC 4.8HRZNHorizon Technology Finance CorporationQOC 4.8PRKRParkerVision, Inc.QOC 4.8NVDANVIDIA CorporationQOC 10.0

Read investment analysis: THMG · UONE · HSLV · FWDI · HRZN · PRKR · NVDA

What Else Do Investors Ask About Freenome, Inc.’s Valuation?

What is Freenome, Inc.'s intrinsic value in 2026?

CirclFi does not yet have enough active models to publish a median fair value for Freenome, Inc. (FRNM). The Quality of Company score is 4.8/10 across 32 fundamental signals. All models use SEC EDGAR filings updated daily. See our methodology page for how each model works.

Is FRNM overvalued or undervalued right now?

At $13.94, 0 of 1 active models suggest FRNM may be undervalued, while 1 indicate potential overvaluation. The assessment depends on which methodology best fits Freenome, Inc.'s business model in Diagnostics & Research.

What does a Quality of Company score of 4.8 mean for FRNM?

Freenome, Inc.'s QOC of 4.8/10 reflects 32 fundamental signals: profitability margins, revenue growth consistency, balance sheet leverage, free cash flow generation, and capital allocation efficiency. Scores below 5 flag potential fundamental weaknesses requiring careful analysis.

How many valuation models does CirclFi run on FRNM?

CirclFi analyzes FRNM with 13 institutional-grade models daily: Bayesian DCF (Monte Carlo + jump-diffusion), EPV (Greenwald zero-growth), EROIC Spread (McKinsey reinvestment), First Chicago (3-scenario), Markov DDM (regime-switching), ML-RIV (machine learning residual income), Dynamic NAV (asset-based), PWERM (option-theoretic), Regime Cross-Sectional (relative), Sentiment SOTP (hybrid), CUCE Ensemble (meta-model), FTNN Topology (neural network), and RCMH-DCF (conditional regime). Currently 1 of 13 are active for this stock. Read the full methodology →

Is FRNM a value trap in 2026?

Freenome, Inc.'s Value Trap score is 32/100 (LOW). This low score indicates the current valuation is not artificially depressed by fundamental deterioration, suggesting genuine opportunity rather than a trap. Browse stocks by value-trap risk →

Cite this analysis — “CirclFi assigns Freenome, Inc. (FRNM) a Quality of Company score of 4.8/10 across 32 fundamental signals as of 2026-08-27.” Source: circlfi.com/stock/FRNM/ · Methodology
Primary sources for this FRNM valuation
  • Financial statements: Freenome, Inc. 10-K and 10-Q filings on SEC EDGAR (CIK 0002017526) — 700+ standardized XBRL tags, published by the U.S. Securities and Exchange Commission.
  • Discount-rate inputs: FRED, Federal Reserve Bank of St. Louis — risk-free rates, VIX, yield curve, inflation.
  • News sentiment: The GDELT Project — global media tone, input to the Sentiment SOTP model.
  • Model definitions: CirclFi methodology — the published specification for all 13 models, including the academic sources each one implements.

Market data for FRNM as of ; valuations recomputed .